Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ForDoz","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Gets Exclusive Rights to Market and Distribute 2 Complex Injectable Assets from ForDoz Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by ForDoz

    Menu

    ForDoz

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ForDoz

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®

              Details:

              LipoMedix's lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex injectable products.

              Lead Product(s): Pegylated liposomal Mitomycin-c prodrug,Capecitabine

              Therapeutic Area: Oncology Product Name: Promitil

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: LipoMedix

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ForDoz

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix

              Details:

              Fordoz will support LipoMedix to develop and manufacture Promitil in the United States. Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy.

              Lead Product(s): Pegylated liposomal Mitomycin-c prodrug,Capecitabine

              Therapeutic Area: Oncology Product Name: Promitil

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: LipoMedix

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ForDoz

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lupin Gets Exclusive Rights to Market and Distribute 2 Complex Injectable Assets from ForDoz Pharma

              Details:

              Agreement provides Lupin the exclusive rights to market and distribute 2 complex injectable assets in advanced stages of development in the US and its territories.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Lupin Ltd

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY